Modern trends in cancer vaccinotherapy

Experimental Oncology

Volumn 22, Issue 3, 2000, Pages 99-109

  Shlyakhovenko, V A ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Antigens; Cancer vaccines; Immunity; Resistance; Therapy

Indexed keywords

CANCER VACCINE; CELL ADHESION MOLECULE; GLYCOPEPTIDE; LIPOSOME; NUCLEIC ACID; RECOMBINANT VACCINE; TUMOR ANTIGEN;

ANTIGEN ANTIBODY COMPLEX; CANCER THERAPY; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE ANALYSIS; REVIEW; TUMOR CELL CULTURE; TUMOR IMMUNITY; VACCINATION;

EID: 0033746987     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Zitvogel L, Regnault A, Lozier A. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594-600.
2. DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 1998; 185: 65-74.
3. Kageshita T, Wang Z, Calorini L, et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 1993; 53: 3349-54.
4. Cordon-Cardo C, Fuks Z, Drobnjak M, et al. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991; 51: 6372-80.
5. Herlyn D, Birebent B. Advances in cancer vaccine development. Ann Med 1999; 31: 66-78.
6. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T-lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 3961-8.
7. Staveley O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-83.
8. Antonia SJ, Extermann M, Flavell RA. Immunologic nonresponsiveness to tumors. Crit Rev Oncol 1998; 9: 35-41.
9. Fuchs EJ, Marzinger P. Is cancer dangerous to the immune system? Sem Immunol 1996; 8: 271-80.
10. Herlyn D, Powe J, Ross AH, et al. Inhibition of human tumor growth by IgG2a monoclonal antibodies correlates with antibody density on tumor cells. J Immunol 1985; 134: 1300-4.
11. Somasundaram R, Zaloudic J, Jacob L, et al. Induction of antigen-specific T- and B-celimmunity in colon carcinoma patients by anti-idiotypic antibody J Immunol 1995; 155: 3253-61.
12. Shiota G, Ishida M, Noguchi N, et al. Clinical significance of serum p53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol 1998; 99: 41-51.
13. Weller M, Bornemann A, Stander M, et al. Humoral immune response to 53 in malignant glioma. J Neurol 1998; 245: 169-72.
14. Agrawal B, Reddish MA, Longenecker BM. In vitro induction of MUC-1 peptide-specific types 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 1996; 157: 2089-95.
15. Nakamura H, Hinoda Y, Nakagawa N, et al. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 1998; 33: 354-61.
16. Richards ER, Devine PL, Quin RJ, et al. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998; 46: 245-52.
17. Kawashima I, Tsai V, Southwood S, et al. Identification of GP100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer 1998; 78: 518-24.
18. Zajac P, Oertli D, Spagnoli G, et al. Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding Mart-1/Melan-A 27-35 epitope. Int J Cancer 1997; 71: 491-6.
19. Lane DP. Cancer: p53, guardian of the genome. Nature 1992; 358: 15-6.
20. Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987; 327: 298-303.
21. Robbins PF, El-Gamil M, Li YF et al. A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183: 1185-92.
22. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 1990; 87: 4207-11.
23. Peace DJ, Smith JW, Chen W, et al. Lysis of ras oncogene-transformed cells by specific cytotoxic T-lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med 1994; 179: 473-9.
24. Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 1997; 57: 1419-24.
25. Hermans IF, Daish A, Yang J, et et. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res 1998; 58: 3909-17.
26. Shevach EM. Accesory molecules. In: W. Paul (ed), Fundamental Immunology. New York, Raven, 1989: 413-44.
27. Mor G, Gutierez LS, Eliza M, et al. Fas-Fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol 1998; 140: 89-94.
28. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-34.
29. Robertson MJ, Caligiuri MA, Manley TJ. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol 1990; 145: 3194-201.
30. Timonen T, Gahmberg CG, Patarroy O. Participation of CD11a-c/CD18, CD2 and RGD-binding receptors in endogenous and interleukin-2-stimulated NK activity of CD3-ncgative large granular lymphocytes. Int J Cancer 1990; 46: 1035-40.
31. + T-lymphocytes that express F receptors for IgG (CD16/Leu-11 antigen). J Exp Med 1985; 162: 2089-106.
32. Houchins JP, Yabe T, McSherry C, Bach FN. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991; 173: 1017-20.
33. Yabe T, McSherry C, Bach FN. A multigene family on human chromosome 12 encodes natural killer-cell lectins. Immunogenetics 1993; 37: 455-60.
34. Lanier LL, Buck DW, Rhodes L. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J Exp Med 1998; 167: 1572-85.
35. Imboden JB, Ericsson EC, McCutcheon M, et al. Iden-tification and characterization of a cell-surface molecule that is selectively induced on rat lymphokine-activated killer cells. J Immunol 1989; 143: 3100-3.
36. Garni-Wagner BA, Purohit A, Mathew PA. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Immunol 1993; 151: 60-70.
37. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 1993; 178: 1397-06.
38. Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigens on natural killer cells and granulocytes. J Immunol 1988; 141: 3478-85.
39. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor b and reversal by recombinant tumor necrosis factor a. J Exp Med 1987; 166: 991-8.
40. Torre-Amione G, Beauchamp RD, Koeppen H, et al. A highly immunogenic tumor transfected with a murine TGF-β cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87:1486-90.
41. Strand S, Hoffman WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells -a mechanism of immune evasion? Nat Med 1996; 2: 1361-6.
42. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor b antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909-14.
43. Pardoll DM. Cancer vaccines. Nat Med 1998; 4: 525-31.
44. Lindauer M, Stanislawski T, Haubler A, et al. The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes. J Mol Med 1998; 76: 32-47.
45. Chen L, Ashe S, Brady WA, et al. Costimulation of a antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-102.
46. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-70.
47. Cavallo F, Martin-Fontecha A, Bellone RI, et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory responce. Eur J Immunol 1995; 25: 1154-62.
48. Huang AYC, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-5.
49. Huang AYC, Bruce AT, Pardoll DM, et al. Docs B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996; 183: 769-76.
50. Diederichsen AC, Stenholm AC, Kronborg O, et al. Immunisation of colorectal cancer patients with autologous tumour cells. Oncol Rep 1998; 5: 823-6.
51. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486-93.
52. Mitchell MS. A personal (biased) perspective on cancer "vaccines". Oncol Res 1997; 9: 459-65.
53. Chakraborty NG, Sporn JR, Tortora AF. Immunization with a tumor-cell-lysate-loaded autologous -antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 1998; 47: 58-64.
54. Bystryn JC, Jacobsen S, Harris M. Preparation and characterization of a polyvalent human melanoma antigen vaccine. Biol Response Mod 1986; 5: 211-24.
55. Hodi FS, Dranoff G. Genetically modified tumor cell vaccines. Surg Oncol Clin N Am 1998; 7: 471-85.
56. Hansson J, Ohlsson L, Persson R. Genetically engineered superantigens as tolerable antitumor agents. Immunology 1997; 94: 2489-94.
57. Govindaswami R, Rao K, Dongxu Q. A novel and effecient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconjugate J 1998; 15: 217-21.
58. Hariharan K, Braslawsky G, Barnett RS. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 1998; 12: 1229-35.
59. Berd D, Kairys J, Dunton C. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 1998; 25: 646-53.
60. Schmidt W, Buschle M, Zauner W. Cell-free tumor antigen peptide-based cancer vaccines. Proc Natl Acad Sci USA 1997; 94: 3262-7.
61. Ma Y, Yuan M, Fei L. Anti-tumor activity and immune responses induced by human cancer-associated mucin core peptide. Chung Hua Chung Liu Tsa Chin 1996; 18: 419-21.
62. Samuel J, Budzynski WA, Reddish MA. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Int J Cancer 1998; 75: 295-302.
63. Ravindranath MH, Morton DL. Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines. Cancer Invest 1997; 15: 491-9.
64. Ruiz PJ, Wolkowicz R, Waisman A. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med 1998; 4: 710-2.
65. Foon KA, John WJ, Chakraborty M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997; 3: 1267-76.
66. Sandler B, Smirnoff P, Shani A, et al. The role of the soluble p53 antigen and its autoantibodies as markers for diagnosis of colon cancer: A comparative study I. J Mol Med 1998; 1: 453-7.
67. Menoret A, Chandawarkar R. Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. Semin Oncol 1998; 25: 654-60.
68. Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Colorectal cancer vaccines. Br J Surg 1998; 85: 149-54.
69. Kudryashov V, Kim HM, Ragupathi G. Immunogenicity of synthetic conjugates of Lewis oligosaccharide with proteins in mice: towards the design of anticancer vaccines. Cancer Immunol Immunother 1998; 45: 281-6.
70. Okamoto T, Wang HJ, Hoon DS. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccinelinked to the human leukocyte antigen phenotype of patients. J Clin Oncol 1998; 16: 1430-7.
71. Dyall R, Bowne WB, Weber LW. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188: 1553-61.
72. Browning M, Dunnion D. HLA and cancer: implications for cancer immunotherapy and vaccination. Eur J Immunogenet 1997; 24: 293-312.
73. Tendler Y, Ben-Hur H, Gurevich P. Role of apoptosis, proliferating cell nuclear antigen and p53 protein in the immune response of rat colon cells to cancer and vaccination with anti-p53 polyclonal antibodies. Anticancer Res 1997; 17: 4653-7.
74. DeMatos P, Abdel-Wahab Z, Vervaert C. Pulsing of dendritic cells with cell lysates from cither B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998; 68: 79-91.
75. Brenner MK, Heslop HE, Rooney CM. Gene and cell transfer for specific immunotherapy. Vox Sanguinis 1998; 74: (Suppl 2): 87-90.
76. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysate mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482-7.
77. Okada H, Tahara H, Shurin MR. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998; 78: 196-201.
78. Celluzzi CM, Falo Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160: 3081-5.
79. Nair SK, Boczkowski D, Snyder D. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 1997; 27: 589-97.
80. Pardoll DM. Paracrine cytokine adjuvants in cancer chemotherapy. Annu Rev Immunol 1995; 13: 399-412.
81. Rosenberg SA, Blaese RM, Brenner MK. Human gene marker/therapy clinical protocols. Hum Gene Ther 1997; 8: 2301-6.
82. + blood progenitors for anticancer therapy. Exp Hematol 1995; 23: 1463-71.
83. Gluckman JC, Canque B, Chapius F. In vitro generation of human dendritic cells and cell therapy. Cytokines Cell Mol Ther 1997; 3: 187-96.
84. Jakob T, Walker PS, Krieg AM. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042-9.
85. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46: 82-7.
86. Ashley DM, Faiola B, Nair S. Bone marrow-generated dendritic-cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186: 1177-82.
87. Chakraborty NG, Sporn JR, Tortora AF. Immunization with a tumor-cells-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 1998; 47: 58-64.
88. Tsai V, Kawashima I, Keogh E. In vitro immunization and expansion and antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 1998; 18: 65-75.
89. Gong J, Chen D, Kashiwaba M. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-61.
90. Toes RE, van der Voort EI, Schoenberger SP. Enhancement of tumor outgrowth through CTL totalization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998; 160: 4449-56.
91. Moelling K. DNA for genetic vaccination and therapy. Cytokines Cell Mol Ther 1997; 3; 127-35.
92. Weber LW, Bowne WB, Wolchok JD. Tumor immutity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998; 102: 1258-64.
93. Wolff JA, Malone RW, Williams P. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Science 1990; 247: 1465-8.
94. Encke J, Putlitz J, Wands J. DNA vaccines. Intervirology 1999; 42: 117-24.
95. Wollf JA, Ludtke JJ, Acsadi G. Direct genes transfer into mouse muscle in vivo. Hum Mol Genet 1992; 1: 363-9.
96. Xu D, Liew FY. Genetic vaccination against leishmaniasis. Vaccine 1994; 12: 1534-8.
97. Park J. Effective immunotherapy of cancer by DNA vaccination. Mol Cells 1999; 31: 9 384-91.
98. Tang DC, Devit M, Jonston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-4.
99. Fynnan EF, Webster RG, Fuller DH. DNA vaccines: a novel approach to immunization. Proc Natl Acad Sci USA 1993; 90: 11478-82.
100. Tuting T, Storkus WJ, Falo LD. DNA immunization targeting the skin: molecular control of adaptive immunity. J Invest Dermatol 1998; 111: 183-8.
101. Panje WR, Hier MP, Garman GR. Electroporation therapy of head and neck cancer. Ann Otol Rhinol Laryngol 1998; 107: 779-85.
102. Chen L, McGown P, Hellstrom E. Tumor immunogeneticy determines the effect of B7 costimulation on T cell-mediated tumor immunity. Exp Med 1994; 179: 523-32.
103. Wallich R, Bulbus N, Hammerling GJ. Abrogation of metastatic properties of tumoyr cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985; 315: 301-5.
104. Hock H, Dorsch M, Kunzendorf H. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma Proc Natl Acad Sci USA 1993; 90: 2774-8.
105. Ohno K, Yoshizawa H, Tsukada H. Adoptive immunotherapy with tumor-specific T-lymphocytes generated from cytokine gene modified tumor-primed lymph node cells. J Immunol 1990; 156: 3875-81.
106. Gunzburg WH, Salmons B. Development of retroviral vectors as safe, targeted gene delivery systems. J Mol Medicine 1996; 74: 171-82.
107. Descumps V, Duffour MT, Mathien MC. Strategies for cancer gene therapy using adenoviral vectors. J Mol Medicine 1996; 74: 183-9.
108. Roth J, Dittmer D, Rea D. P53 as a target for cancer vaccines: recombinant canaripox virus vectors exspressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996; 93: 4781-6.
109. Chen SH, Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-81.
110. Ealovega MW, Meginnis PK, Sumantran VN. bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res 1996; 56: 1965-9.
111. Temin HM. Overview of biological effects of addition of DNA molecules to cells. Dev Biol Stand 1998; 93: 37-44.
112. Escola JM, Kleijmeer MJ, Stoorvogel W. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998; 273: 20121-7.
113. Rizzo S, Silvotti MG, Martano F. Long term primary human tumor cell cultures and mixed autologous tumor-lymphocyte cultures for adoptive specific antitumoral immunotherapy. Anticancer Res 1998; 18: 41-4.
114. Kwak LW, Pennington R, Boni L Cutting edge: Liposomal formulation of a self-lymphoma antigen induced potent protective antitumor immunity. J Immunol 1998; 160: 3637-41.
115. + T cells. J Surg Oncol 1998; 67: 221-7.
116. Kimoto T. Pathological observations during treatment with the biological response modifier Maruyama vaccine in cancer: implications for collagen production in the prevention of cancer invasion and metastasis. Cancer Detect Prev 1998; 22: 340-9.
117. Omar AR, Schat KA, Lee LF. Cytotoxic T lymphocyte response in chickens immunized with a recombinant fowlpox virus expressing Marek's disease herpesvirus glycoprotein B. Vet Immunol Immunopathol 1998; 62: 73-82.
118. Skornick Y, Kurman CC, Sindelar WF. Active immunization of hamsters against pancreatic carcinoma with lipid-treated cells or their shed antigens. Cancer Res 1984; 44: 946-8.
119. Scornick YG, Rong GH, Sindelar WF. Active immunotherapy of human solid tumor with autologous cells treated with cholesteryl hemisuccinate. A Phase 1 studies. Cancer 1986; 58: 650-4.
120. Shinitzky M, Skornick Y, Haran-Ghera N. Effective tumor immunization induced by cells of elevated membrane-lipid microviscosity. Proc Natl Acad Sci USA 1979; 76: 5313-6.
121. Eisental A, Ramakrishna V, Skornick Y. Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking. Cancer Immunol Immunother 1993; 36: 300-6.
122. Ramakrishna V, Eisenthal A, Skornick Y, Shinitzky M. Increased projection of MHC and tumor antigens in murine B 16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking. Cancer Immunol Immunother 1993; 36: 293-9.
123. Hallez S, Detremmerie O, Giannouli C. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 1999; 81: 428-37
124. Kemp JD. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the trasferrin receptor. Histol Histophatol 1997; 12: 291-6.
125. Wellinghausen N, Rink L. The significance of zinc for leukocyte biology. J Leukoc Biol 1998; 64: 571-7.